{"nctId":"NCT01002573","briefTitle":"Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients","startDateStruct":{"date":"2010-07"},"conditions":["Fever"],"count":118,"armGroups":[{"label":"ibuprofen","type":"EXPERIMENTAL","interventionNames":["Drug: ibuprofen"]},{"label":"Acetaminophen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: acetaminophen"]}],"interventions":[{"name":"ibuprofen","otherNames":[]},{"name":"acetaminophen","otherNames":["APAP (acetaminophen)","paracetamol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Have written informed consent provided by legal parent, guardian, or authorized agent prior to participation in the study or study-only related procedures.\n2. Be between birth (28 weeks to \\< 40 weeks gestational age) to ≤ 16 years of age.\n3. Have new (less than 7 days) onset of fever, documented by temperature greater than or equal to 101.0 ºF (38.3 ºC).\n\nExclusion Criteria:\n\n1. Have inadequate intravenous access.\n2. Have received antipyretic drug therapy within 2 hours before dosing.\n3. Have any history of allergy or hypersensitivity to NSAIDs or aspirin.\n4. Have received another investigational drug within the past 30 days.\n5. Be otherwise unsuitable for the study, in the opinion of the Investigator.\n6. Have a fever due to hyperthermia.\n7. Pregnant or nursing.","healthyVolunteers":false,"sex":"ALL","maximumAge":"16 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Fever Reduction","description":"Treatment of fever as measured by the area under the change in temperature versus time curve during the first two hours of treatment (AUC0-2)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"1.11"},{"groupId":"OG001","value":"-0.9","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Temperature After the First 30 Minutes of Treatment","description":"Change in temperature in patients receiving intravenous ibuprofen and acetaminophen (APAP) after the first 30 minutes of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.50"},{"groupId":"OG001","value":"-0.3","spread":"0.49"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Temperature After the First 60 Minutes of Treatment","description":"Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 60 minutes of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.69"},{"groupId":"OG001","value":"-0.5","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Change in Temperature","description":"Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 4 hours of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"0.92"},{"groupId":"OG001","value":"-0.9","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Temperature After the First Four Hours of Treatment","description":"Change in temperature during the first 4 hours of treatment by assessing the area under the change in temperature versus time curve during the first four hours of treatment (AUC0-4)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"2.59"},{"groupId":"OG001","value":"-2.6","spread":"2.02"}]}]}]},{"type":"SECONDARY","title":"Time to Afebrility (in Hours)","description":"Tme to afebrility (temperature less than 100.4 ºF \\[38 ºC\\]) in patients receiving intravenous ibuprofen and APAP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"0.47"},{"groupId":"OG001","value":"3.3","spread":"0.67"}]}]}]},{"type":"SECONDARY","title":"Number of Afebrile and Febrile Subject at 4 Hours Post-Dose","description":"Number of Afebrile and Febrile Subject at 4 Hours Following Treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":47},"commonTop":["Vomiting","Diarrhoea","Nausea","Infusion Site Pain","Aspartate Aminotransferase Increased"]}}}